Janice Mehnert, MD
NYU Langone Health · New York Langone Health
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Janice Mehnert, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:11 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05428007 · Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV MelanomaNYU Langone Health · recruiting · Melanoma, Unresectable Melanoma · principal investigator
- Ph2NCT03999749 · A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV MelanomaNYU Langone Health · active not recruiting · Melanoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:11 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.